No Data
No Data
Express News | Zyversa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome Asc Inhibitor Ic 100
Express News | ZyVersa Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 7.59%
ZyVersa Therapeutics Announces Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to Be Held Virtually on July 15, 2024
Peering Into ZyVersa Therapeutics's Recent Short Interest
Express News | Zyversa Therapeutics: Inflammasome Asc Inhibitor Ic 100's Preclinical Program Nearing Completion, Glp Toxicology Studies Expected to Begin H1-2024
No Data